Sphingosine Analogs and Protein Phosphatase 2A as a Molecular Targeted Cancer Therapy: A Mini Systematic Review

Author(s): Thomas Mayerhofer, Rajesh Kumar Jha*

Journal Name: Clinical Cancer Drugs

Volume 7 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Regulation of protein phosphatase 2A (PP2A) plays an important role in hematologic and solid neoplasms. Therefore, the use of sphingosine analogs as anti-neoplastic drugs has shown potential due to their role as PP2A activators.

Objective: Investigation of whether sphingosine analogs bind to endogenous inhibitor proteins of PP2A, such as I2 PP2A/SET and/or CIP2A, and whether this binding reactivates PP2A, allowing it to resume its role as a tumor suppressor.

Methods: Literature from the PubMed database was searched and those articles related to PP2A and sphingosine analogs were reviewed.

Results: Utilization of sphingosine analogs in hematologic and solid neoplasms revealed numerous mechanisms of inducing cell death. Regulation of PP2A through modulation of I2 PP2A/SET and/or CIP2A was demonstrated in a variety of neoplastic processes; however, unique mechanisms such as cell necrosis via the production of reactive oxygen species was also appreciated.

Conclusion: Only certain malignancies expressed endogenous inhibitor proteins, yet sphingosine analogs were able to induce cell death in neoplasms that did not express these proteins. This suggests that sphingosine analogs may be utilized for anti-neoplastic therapy via reactivation of PP2A however, it is not the exclusive mechanism for inducing cell death. Further investigation of sphingosine analogs as a novel or adjunctive chemotherapeutic treatment is warranted.

Keywords: PP2A, I2 PP2A/SET, CIP2A, sphingosine analogs, FTY720, S1PR, neoplasm, leukemia.

[1]
Organization for Economic Co-operation and Development [Internet]. OECD better life index http://www.oecdbetterlifeindex.org [cited 2018 Dec 9].
[2]
Centers for Disease Control and Prevention [Internet]. CDC Leading causes of death 2017 https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm [cited 2018 Dec 9].
[3]
US Cancer Statistics Working Group. US cancer statistics data visualizations tool, based on Nov 2018 submission data (1999-2016): US department of health and human services, centers for disease control and prevention and national cancer institute 2018. www.cdc.gov/cancer/dataviz [cited 2018 Dec 9].
[4]
The American Cancer Society, Inc. [Internet]. Evolution of Cancer Treatments: Targeted Therapy 2014 https://www. cancer.org/cancer/cancer-basics/history-of-cancer/cancer-treatment-targeted-therapy.html [cited 2018 Dec 9].
[5]
The American Cancer Society, Inc. [Internet]. Chemotherapy Side Effects 2016. https://www.cancer.org/treatment/treatments-and-side-effects/treatmenttypes/chemotherapy/chemotherapy-side-effects.html [cited 2018 Dec10].
[6]
Colagiuri B, Dhillon H, Butow PN, Jansen J, Cox K, Jacquet J. Does assessing patients’ expectancies about chemotherapy side effects influence their occurrence? J Pain Symptom Manage 2013; 46(2): 275-81.
[http://dx.doi.org/10.1016/j.jpainsymman.2012.07.013 ] [PMID: 23149081]
[7]
Dietrich E, Antoniades K. Molecularly targeted drugs for the treatment of cancer: Oral complications and pathophysiology. Hippokratia 2012; 16(3): 196-9.
[PMID: 23935282]
[8]
The American Cancer Society, Inc. Cancer in the Twenty-first Century 2014.https://www.cancer.org/cancer/cancer-basics/history-of-cancer/twenty-first-century-and-beyond.html [cited 2018 Dec10].
[9]
O’Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994-1004.
[http://dx.doi.org/10.1056/NEJMoa022457 ] [PMID: 12637609]
[10]
Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV. Leukemia 2015; 29(5): 1123-32.
[http://dx.doi.org/10.1038/leu.2015.36 ] [PMID: 25676422]
[11]
Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract 2014.: 2014357027
[http://dx.doi.org/10.1155/2014/357027 ] [PMID: 24963404]
[12]
Cohen P, Cohen PT. Protein phosphatases come of age. J Biol Chem 1989; 264(36): 21435-8.
[PMID: 2557326]
[13]
Smith AM, Dun MD, Lee EM, et al. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget 2016; 7(30): 47465-78.
[http://dx.doi.org/10.18632/oncotarget.10167 ] [PMID: 27329844]
[14]
Xie F, Bao X, Yu J, et al. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK. Oncotarget 2015; 6(28): 25660-76.
[http://dx.doi.org/10.18632/oncotarget.4705 ] [PMID: 26308070]
[15]
Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996; 271(19): 11059-62.
[http://dx.doi.org/10.1074/jbc.271.19.11059 ] [PMID: 8626647]
[16]
Ponnusamy S, Meyers-Needham M, Senkal CE, et al. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 2010; 6(10): 1603-24.
[http://dx.doi.org/10.2217/fon.10.116 ] [PMID: 21062159]
[17]
Mukhopadhyay A, Saddoughi SA, Song P, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2009; 23(3): 751-63.
[http://dx.doi.org/10.1096/fj.08-120550 ] [PMID: 19028839]
[18]
Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evid 2011; 6: 13-21.
[http://dx.doi.org/10.2147/CE.S10101 ] [PMID: 21468239]
[19]
Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 2011; 74(4): 900-7.
[http://dx.doi.org/10.1021/np2000528 ] [PMID: 21456524]
[20]
Zonta F, Pagano MA, Trentin L, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood 2015; 125(24): 3747-55.
[http://dx.doi.org/10.1182/blood-2014-12-619155 ] [PMID: 25931585]
[21]
Oaks JJ, Santhanam R, Walker CJ, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013; 122(11): 1923-34.
[http://dx.doi.org/10.1182/blood-2013-03-492181 ] [PMID: 23926298]
[22]
Chen L, Luo LF, Lu J, et al. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. PLoS One 2014; 9(7): e103033
[http://dx.doi.org/10.1371/journal.pone.0103033 ] [PMID: 25050888]
[23]
The American Cancer Society, Inc. Acute myeloid leukemia (AML) subtypes and prognostic factors 2018. https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.html [cited 2018 Dec10].
[24]
Pippa R, Dominguez A, Christensen DJ, et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 2014; 28(9): 1915-8.
[http://dx.doi.org/10.1038/leu.2014.141 ] [PMID: 24781014]
[25]
Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, et al. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. J Biomed Nanotechnol 2015; 11(4): 691-701.
[http://dx.doi.org/10.1166/jbn.2015.1944 ] [PMID: 26310075]
[26]
Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59(6): 478-90.
[http://dx.doi.org/10.1016/j.addr.2007.04.007 ] [PMID: 17543416]
[27]
Mao Y, Wang J, Zhao Y, et al. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine (Lond) 2014; 10(2): 393-400.
[http://dx.doi.org/10.1016/j.nano.2013.08.001 ] [PMID: 23969101]
[28]
The American Cancer Society, Inc. What’s New in Acute Myeloid Leukemia (AML) Research? 2018. https://www.cancer.org/cancer/acute-myeloid-leukemia/about/new-research.html [cited 2018 Dec10].
[29]
Shouse G, de Necochea-Campion R, Mirshahidi S, Liu X, Chen CS. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget 2016; 7(38): 61081-92.
[http://dx.doi.org/10.18632/oncotarget.11209 ] [PMID: 27531894]
[30]
Ruvolo PP, Ruvolo VR, Jacamo R, et al. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta 2014; 1843(9): 1969-77.
[http://dx.doi.org/10.1016/j.bbamcr.2014.05.006 ] [PMID: 24858343]
[31]
Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123(10): 4144-57.
[http://dx.doi.org/10.1172/JCI68951 ] [PMID: 23999433]
[32]
Kiyota M, Kuroda J, Yamamoto-Sugitani M, et al. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis 2013; 18(11): 1437-46.
[http://dx.doi.org/10.1007/s10495-013-0882-y ] [PMID: 23851982]
[33]
Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279(14): 13839-48.
[http://dx.doi.org/10.1074/jbc.M311743200 ] [PMID: 14732717]
[34]
McCracken AN, McMonigle RJ, Tessier J, et al. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. Leukemia 2017; 31(3): 669-77.
[http://dx.doi.org/10.1038/leu.2016.244 ] [PMID: 27573555]
[35]
Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60(2): 181-95.
[http://dx.doi.org/10.1124/pr.107.07113 ] [PMID: 18552276]
[36]
Mani R, Mao Y, Frissora FW, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 2015; 29(2): 346-55.
[http://dx.doi.org/10.1038/leu.2014.199 ] [PMID: 24947019]
[37]
Cristóbal I, González-Alonso P, Daoud L, et al. Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs 2015; 13(6): 3276-86.
[http://dx.doi.org/10.3390/md13063276 ] [PMID: 26023836]
[38]
Teng HW, Yang SH, Lin JK, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012; 16(5): 1037-47.
[http://dx.doi.org/10.1007/s11605-012-1828-3 ] [PMID: 22328001]
[39]
Cristóbal I, Manso R, Rincón R, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 2014; 13(4): 938-47.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0150 ] [PMID: 24448818]
[40]
Li J, Wang SW, Zhang DS, et al. FTY720-induced enhancement of autophagy protects cells from FTY720 cytotoxicity in colorectal cancer. Oncol Rep 2016; 35(5): 2833-42.
[http://dx.doi.org/10.3892/or.2016.4668 ] [PMID: 26985637]
[41]
Liu H, Gu Y, Wang H, et al. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget 2015; 6(17): 14913-25.
[http://dx.doi.org/10.18632/oncotarget.3818 ] [PMID: 25945834]
[42]
Kubota D, Yoshida A, Kawai A, Kondo T. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. J Proteome Res 2014; 13(5): 2250-61.
[http://dx.doi.org/10.1021/pr400929h ] [PMID: 24621013]
[43]
Lee EJ, Park MK, Kim HJ, et al. Epithelial membrane protein 2 regulates sphingosylphosphorylcholine-induced keratin 8 phosphorylation and reorganization: Changes of PP2A expression by interaction with alpha4 and caveolin-1 in lung cancer cells. Biochim Biophys Acta 2016; 1863(6 Pt A): 1157-69.
[http://dx.doi.org/10.1016/j.bbamcr.2016.02.007 ] [PMID: 26876307]
[44]
Park MK, Park S, Kim HJ, et al. Novel effects of FTY720 on perinuclear reorganization of keratin network induced by sphingosylphosphorylcholine: Involvement of protein phosphatase 2A and G-protein-coupled receptor-12. Eur J Pharmacol 2016; 775: 86-95.
[http://dx.doi.org/10.1016/j.ejphar.2016.02.024 ] [PMID: 26872988]
[45]
Velmurugan BK, Lee CH, Chiang SL, et al. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential. J Cell Physiol 2018; 233(2): 1300-11.
[http://dx.doi.org/10.1002/jcp.26001 ] [PMID: 28516459]
[46]
Tay KH, Liu X, Chi M, et al. Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720. Pigment Cell Melanoma Res 2015; 28(2): 171-83.
[http://dx.doi.org/10.1111/pcmr.12326 ] [PMID: 25358761]
[47]
Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. Semin Neurol 2013; 33(1): 37-44.
[http://dx.doi.org/10.1055/s-0033-1343794 ] [PMID: 23709211]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 2
Year: 2020
Published on: 04 May, 2020
Page: [78 - 88]
Pages: 11
DOI: 10.2174/2212697X07999200504110631
Price: $25

Article Metrics

PDF: 219
HTML: 2